Co‐Delivery Evodiamine‐Porphyrin Nano‐Drug to Enhance Photodynamic‐Chemo‐Immunotherapy for Triple‐Negative Breast Cancer Treatment
Advanced Healthcare Materials · 2026-01 · 15 (3)
DOI: 10.1002/adhm.202503039 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 23.09.2025. Verfasst von Qiang Zhou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Second Affiliated Hospital of Army Medical University, Chongqing, 400037, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Photochemotherapy, Immunotherapy, Porphyrins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Natural Science Foundation of Chongqing, Science and Technology Research project of the Chongqing Education Commission, Young Doctor Research project of the Second Affiliated Hospital of Army Medical University.
Abstract (Originalsprache)
Immunotherapy is a promising treatment for triple‐negative breast cancer (TNBC), but the immunosuppressive tumor microenvironment (TME) compromises its efficacy. Therefore, the nano‐drug TPGS@EVO/Ppa (TEP) is designed and prepared to achieve chemotherapy and enhance immunotherapy. Evodiamine (EVO) demonstrates chemotherapeutic efficacy and enhanced CD8 + T cell infiltration within the TME. Additionally, laser irradiation of Pyropheophorbide‐a (Ppa) generates singlet oxygen, promoting tumor cell apoptosis and inducing immunogenic cell death (ICD). In vitro and in vivo experiments demonstrate that TEP exhibits significant cytotoxicity against 4T1 tumor cells and markedly inhibits tumor growth. Furthermore, TEP promotes the release of damage‐associated molecular patterns (DAMPs) such as calreticulin (CRT), high mobility group box 1 protein (HMGB1), and adenosine triphosphate (ATP), which stimulates dendritic cells (DCs) maturation and activate adaptive immunity. Bilateral tumor experiments reveal that the combination therapy significantly increases the proportions of CD4 + and CD8 + T cells in tumors and central memory T cells (TCMs) in the spleen, demonstrating potent immunotherapy efficacy. In summary, TEP emerges as an innovative nano‐drug with exceptional anti‐tumor properties, offering a novel strategy for the treatment of TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Second Affiliated Hospital of Army Medical University, Chongqing, 400037, China.
- Department of Neurology, The Second Affiliated Hospital of Army Medical University, Chongqing, 400037, China.
- Department of Pharmacy, University-Town Hospital of Chongqing Medical University, Chongqing, 401331, China.
ORCID-Profile: Jingbin Huang
Förderung
- Natural Science Foundation of Chongqing
- Science and Technology Research project of the Chongqing Education Commission
- Young Doctor Research project of the Second Affiliated Hospital of Army Medical University
- Natural Science Foundation of Chongqing Municipality
Zitieren
APA
Zhou, Q., Wang, K., Yang, D., Huang, Y., Yu, M., Xie, D., Wang, J., Chen, S., Gong, J., Yang, M., Zhao, Y., & Huang, J. (2026). Co‐Delivery Evodiamine‐Porphyrin Nano‐Drug to Enhance Photodynamic‐Chemo‐Immunotherapy for Triple‐Negative Breast Cancer Treatment. Advanced Healthcare Materials, 15(3). https://doi.org/10.1002/adhm.202503039
Vancouver
Zhou Q, Wang K, Yang D, Huang Y, Yu M, Xie D, et al. Co‐Delivery Evodiamine‐Porphyrin Nano‐Drug to Enhance Photodynamic‐Chemo‐Immunotherapy for Triple‐Negative Breast Cancer Treatment. Advanced Healthcare Materials. 2026;15(3). doi:10.1002/adhm.202503039
BibTeX
@article{Zhou2026,
author = {Zhou, Qiang and Wang, Kui and Yang, Dahong and Huang, Yue and Yu, Mengjun and Xie, Dandan and Wang, Jia and Chen, Shiwen and Gong, Jing and Yang, Min and Zhao, Yu and Huang, Jingbin},
title = {Co‐Delivery Evodiamine‐Porphyrin Nano‐Drug to Enhance Photodynamic‐Chemo‐Immunotherapy for Triple‐Negative Breast Cancer Treatment},
journal = {Advanced Healthcare Materials},
year = {2026},
volume = {15},
number = {3},
doi = {10.1002/adhm.202503039}
}
EUVIMED